From: Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis
Author | Year | Group | N | Age | M/F | Disease | LVEF (%) | Dose | Route | Follow-up | Imaging |
---|---|---|---|---|---|---|---|---|---|---|---|
Bartolucci | 2015 | BMNC | 12 | 58 ± 14 | 9/3 | DCM | ≤ 40 | 8.19 × 106 | IC | – | ECHO |
Control | 11 | 57 ± 11 | 8/3 | ||||||||
Bartolucci | 2017 | BMSC | 15 | 57.33 ± 10.05 | 12/3 | DCM | ≤ 40 | 1 × 106 | IV | 12 months | ECHO |
Control | 15 | 57.2 ± 11.64 | 14/1 | ||||||||
Chang | 2010 | BMNC | 12 | 38.6 ± 9.8 | 16/8 | DCM | – | 2 × 108 | IM | 6 months | ECHO |
Control | 12 | ||||||||||
Chen | 2006 | BMSC | 22 | 59.3 ± 6.8 | 19/3 | IDCM | < 40 | 5 × 106 | IC | 12 months | SPECT |
Control | 62 | 57.8 ± 7.2 | 21/2 | ||||||||
Chen | 2008 | BMNC | 71 | 53 ± 15 | 44/17 | DCM | < 45 | – | IC | 24 months | ECG |
Control | 187 | 54 ± 13 | 136/51 | ||||||||
Hamshere | 2015 | BMNC | 15 | 57.67 ± 12.32 | 10/5 | DCM | < 40 | 2.16 × 108 | IC | 12 months | CMR |
Control | 14 | 54.87 ± 10.86 | 9/6 | ||||||||
Heldman | 2014 | BMNC | 19 | 57.1 ± 10.6 | 18/1 | IDCM | < 50 | – | IM | 12 months | CMR |
Control | 10 | 61.3 ± 9.0 | 10/0 | ||||||||
Henry | 2014 | Ixmyelocel-T | 39 | 64.7 ± 9 | 21/0 | IDCM | < 30 | 2.95 × 108 | IM | 12 months | ECG/SPECT |
Control | 20 | 63.2 ± 12 | 9/0 | ||||||||
Martino | 2015 | BMNC | 82 | 49.6 ± 11.1 | 53/25 | NIDCM | < 35 | 2.36 × 108 | IC | 12 months | ECHO |
Control | 78 | 51 ± 1.11 | 60/22 | ||||||||
Nesteruk | 2017 | BMNC | 114 | 66.7 ± 8.3 | 105/9 | IDCM | < 45 | 3.9 × 106 | IM | 4–14 years | ECHO |
Control | 36 | 68.6 ± 5.78 | 22/4 | ||||||||
Patel | 2016 | Ixmyelocel-T | 59 | 65.3 ± 8.49 | 55/3 | IDCM | < 35 | – | IM | 12 months | ECHO |
Control | 55 | 64.7 ± 9.94 | 45/6 | ||||||||
Perin | 2004 | BMNC | 11 | 56.5 ± 7.8 | 9/2 | DCM | < 40 | – | IM | 12 months | SPECT |
Control | 9 | 58.9 ± 7.6 | 8/1 | ||||||||
Sant’Anna | 2014 | BMNC | 15 | 48.3 ± 8.71 | 13/7 | NIDCM | < 35 | 1.06 × 108 | IM | 12 months | ECHO/CMR |
Control | 9 | 51.6 ± 7.79 | 5/4 | ||||||||
Seth | 2010 | BMNC | 41 | 45 ± 15 | 33/8 | DCM | < 40 | 1.68 × 108 | IC | 36 months | ECHO |
Control | 40 | 49 ± 9 | 35/4 | ||||||||
Song | 2008 | BMSC | 27 |  |  | DCM | < 50 | 2 × 106 | IM | 6 months | Ultrasound |
Control | 25 | Â | Â | ||||||||
Vrtovec | 2011 | BMSC | 28 | 52 ± 8 | 26/2 | DCM | < 30 | 1.13 × 108 | IC | 12 months | ECHO |
Control | 28 | 54 ± 7 | 23/4 | ||||||||
Vrtovec | 2013 | BMSC | 55 | 53 ± 8 | 45/10 | DCM | < 30 | – | IC | 60 months | ECHO |
Control | 55 | 55 ± 7 | 44/11 | ||||||||
Wang | 2006 | BMSC | 12 | 54 ± 11.1 | 9/3 | DCM | < 45 | 5.86 × 105 | IC | 12 months | ECHO |
Control | 12 | 58.4 ± 11 | 8/4 | ||||||||
Xiao | 2017 | BMNC | 16 | 49.5 ± 11.6 | 9/7 | DCM | < 40 | 5.1 × 108 | IC | 3 months | SPECT |
BMSC | 17 | 51.6 ± 12.2 | 12/5 | ||||||||
Control | 20 | 54.4 ± 11.6 | 14/6 | ||||||||
Yan | 2012 | BMSC | 18 | 58 ± 9.9 | 12/6 | DCM | < 40 | 1 × 108 | IC | 12 months | SPECT/ECHO |
Control | 20 | 58.2 ± 9.8 | 14/6 |